Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 15341882)

  • 1. Implementation of capecitabine (Xeloda) into a cancer centre: UK experience.
    Faithfull S; Deery P
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S54-62. PubMed ID: 15341882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications of capecitabine (Xeloda) for cancer nursing practice.
    Gerbrecht BM; Kangas T
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S63-71. PubMed ID: 15341883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of and clinical experience with capecitabine (Xeloda) in the treatment of solid tumours.
    Sternberg CN; Reichardt P; Holland M
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S4-15. PubMed ID: 15341878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A nurse-/pharmacy-led capecitabine clinic for colorectal cancer: results of a prospective audit and retrospective survey of patient experiences.
    MacLeod A; Branch A; Cassidy J; McDonald A; Mohammed N; MacDonald L
    Eur J Oncol Nurs; 2007 Jul; 11(3):247-54. PubMed ID: 17188937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The vital role of education and information in patients receiving capecitabine (Xeloda).
    Chau I; Legge S; Fumoleau P
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S41-53. PubMed ID: 15341881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda).
    Marsé H; Van Cutsem E; Grothey A; Valverde S
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S16-30. PubMed ID: 15341879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral capecitabine (Xeloda) in cancer treatment.
    Doyle DP; Engelking C
    Nurse Pract; 2007 Feb; 32(2):18-21. PubMed ID: 17264789
    [No Abstract]   [Full Text] [Related]  

  • 8. How the new oral antineoplastics affect nursing practice: capecitabine serves to illustrate.
    Szetela AB; Gibson DE
    Am J Nurs; 2007 Dec; 107(12):40-8; quiz 48-9. PubMed ID: 18049060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Canadian experience with capecitabine: partnering with patients to optimize therapy.
    Gerbrecht BM
    Cancer Nurs; 2003 Apr; 26(2):161-7. PubMed ID: 12660565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral capecitabine: bridging the Atlantic divide in colon cancer treatment.
    Van Cutsem E; Verslype C; Tejpar S
    Semin Oncol; 2005 Feb; 32(1):43-51. PubMed ID: 15726505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capecitabine: a new adjuvant option for colorectal cancer.
    Berg DT
    Clin J Oncol Nurs; 2006 Aug; 10(4):479-86. PubMed ID: 16927901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda).
    Lassere Y; Hoff P
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S31-40. PubMed ID: 15341880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is a nurse-led telephone intervention a viable alternative to nurse-led home care and standard care for patients receiving oral capecitabine? Results from a large prospective audit in patients with colorectal cancer.
    Craven O; Hughes CA; Burton A; Saunders MP; Molassiotis A
    Eur J Cancer Care (Engl); 2013 May; 22(3):413-9. PubMed ID: 23527965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capecitabine: an overview of the side effects and their management.
    Saif MW; Katirtzoglou NA; Syrigos KN
    Anticancer Drugs; 2008 Jun; 19(5):447-64. PubMed ID: 18418212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capecitabine non-adherence: exploration of magnitude, nature and contributing factors.
    Bhattacharya D; Easthall C; Willoughby KA; Small M; Watson S
    J Oncol Pharm Pract; 2012 Sep; 18(3):333-42. PubMed ID: 22298660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness.
    Twelves CJ
    Clin Colorectal Cancer; 2006 Nov; 6(4):278-87. PubMed ID: 17241512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
    Cunningham D; Coleman R
    Cancer Treat Rev; 2001 Aug; 27(4):211-20. PubMed ID: 11545541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of a home care nursing program in the symptom management of patients with colorectal and breast cancer receiving oral chemotherapy: a randomized, controlled trial.
    Molassiotis A; Brearley S; Saunders M; Craven O; Wardley A; Farrell C; Swindell R; Todd C; Luker K
    J Clin Oncol; 2009 Dec; 27(36):6191-8. PubMed ID: 19917849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capecitabine in the management of colorectal cancer.
    Maroun JA
    Expert Rev Anticancer Ther; 2001 Oct; 1(3):327-33. PubMed ID: 12113099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.